• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. D. Grimes, MD; P. O. Magner, MD
Parkinson's Disease Clinic Division of Neurology Ottawa Civic Hospital 1053 Carling Ave Ottawa, Ontario Canada K1Y 4E9

Arch Neurol. 1984;41(4):363-364.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The recent report by Buchholz and Kariya¹ again emphasized the now well-established fact that parkinsonism is a potential complication of long-term metoclopramide therapy.^2,3 Domperidone, a peripheral dopaminergic blocking agent, has been documented to have little or no effect on central dopamine receptors⁴ and has been reported to be safe in treating Parkinson's disease.⁵ The drug is now undergoing clinical trials in the United States and Canada to assess its efficacy and safety in controlling levodopa- and dopamine agonist-induced gastric upset in patients with Parkinson's disease. Its protective effect is thought to be on the chemoreceptor trigger zone of the area postrema which lies outside the blood-brain barrier.

Report of a Case.

—We had a case of metoclopramide-induced parkinsonism that resolved with domperidone therapy. A 59-year-old diabetic woman had progressively worsening nausea and vomiting from impaired gastric emptying. Metoclopramide, 20 mg daily, gave complete . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?